Study of Weekly DCF to Treat Advanced Gastric Cancer

• Status: Terminated
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy of weekly docetaxol combined with cisplatin and 5-Fu in patients with AGC.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fudan University
• Treatments: Cisplatin; Docetaxel

Criteria

Inclusion Criteria:

• Age between 18 and 70 years

• Patients with histologically confirmed, unresectable, recurrent and/or metastatic gastric adenocarcinoma

• ECOG performance status ≤1,life expectancy more than 3 months,

• Normal laboratory findings:absolute neutrophil count and platelet count ≥ 2.0×109/L and 80×109/L, respectively, hepatic function (total serum bilirubin ≤ UNL, transaminases ≤ 1.5 times upper normal limit) and renal function (calculated creatinine clearance ≥ 60 ml/min).

• Measurable disease according to the RECIST.

Exclusion Criteria:

• Pregnant or lactating women

• Serious uncontrolled diseases and intercurrent infection

• The evidence of CNS metastasis

• History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix

• Received other chemotherapy regimen after metastasis

• Used taxane in adjuvant settings

• Participated in other clinical trials.